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1. Introduction
Portal hypertension (PH), a detrimental complication of many diseases, is abnormalities in
pre-, intra- or post-hepatic portal venous system. Intrahepatic PH is the most common type,
which is mainly cause by liver cirrhosis [1], liver cancer, and sometimes intrahepatic vascu‐
lar abnormalities [2].
Hepatic venous pressure gradient (HVPG) is the difference between wedged hepatic venous
pressure and infra vena cava pressure. PH is defined as an HVPG higher than 5 mmHg [3].
According to absence or presence of complications (splenomegaly and hypersplenism,
esophageal varices and ascites), PH can be classified into compensated or decompensated
phase. Meanwhile, an HVPG higher than 10 mmHg has been considered as a direct predic‐
tor of decompensation and a 10-year-follow-up study showed the significant worse long-
term survival when HVPG ＞ 10 mmHg [4-6].
In cirrhotic PH, increased intrahepatic vascular resistance (IHVR) is the primary factor [7, 8]
and subsequently increased portal vein inflow (PVI) worsens the situation of PH patients.
This review will focus on the physiopathological changes happened in PH.
2. Correlation between vasoactive substances and IHVR/PVI
2.1. Nitric oxide
Nitric oxide (NO) is a potential vasodilator, produced by NO synthase (NOS). In a rat PH
model induced by Thioacetamide, contraction of hepatic stellate cells, which resulting the
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increase of intrahepatic vascular tone, was inhibited by incubated with nitroflurbiprofen in
vitro, a nitric oxide-releasing cyclooxygenase inhibitor in a dose-dependent manner. In wild-
type BDL mice, expression of NOS, especially eNOS was down-regulated [9]. Moreover, the
significantly elevated total intrahepatic resistance was reduced significantly in vivo by the
drug, indicating a potential role of NO on portal pressure [10]. In another rat PH model in‐
duced by bile-duct-ligation, intrahepatic vascular resistance increased significantly. Besides,
relative level of phos-NOS decreased compared with sham group, leading to an inhibition of
intrahepatic NO, although the relative mRNA level was increased [11]. Intrahepatic NO pro‐
duction is largely mediated by endothelial NO synthase (eNOS) and impaired when cirrho‐
sis and secondary endothelial dysfunction existed, leading to the increase of intrahepatic
vascular resistance. But the inhibition of NO might be the result of up-regulation of caveo‐
lin-1, a down-regulator of eNOS [12].
Contrastingly, extrahepatic NO is increased in PH patients. A clinical trial has shown that
serum nitrate level was positively correlated with clinical presentation, (e.g. pulse rate, jaun‐
dice, hepatic encephalopathy, lower limb edema) and esophageal varices [13]. It is well es‐
tablished that NO results in dilation of splanchnic and systemic circulation as a powerful
vasodilator and blood level of NO is increased as PH progresses [14-16]. Administration of
CCl4 to eNOS(-/-) mice also led to an elevated NO production, which is eNOS independent
[17]. Another study suggested that iNOS might be involved [18].
2.2. Carbon monoxide
Carbon monoxide (CO), a vasodilator producing by heme oxygenases (HOs) from heme
[19],  changes as HO-1 expression altered in PH patients [20,  21],  which shares the same
characters  with  NO [12].  Expression  of  intrahepatic  HO-1  and -2  decreased in  cirrhotic
rats  than  that  in  normal  ones.  In  situ  perfusion  with  CO-releasing  molecule-2,  which
leads to relaxation of hepatic stellate cells, and HO-1 inducer hemin could attenuated in‐
creased IHVR. ZnPP caused a higher IHVR attributing to inhibition of intrahepatic HO-1
in cirrhotic liver[22].
But things are different in splanchnic and systemic circulation. Reportedly, portal vein pres‐
sure (PVP) was significantly higher in bile-duct-ligated rats than that in sham group. Mean‐
while, mRNA and protein level of HO-1 was also elevated significantly in lung [23].A
clinical study has shown an activated HO/CO system in cirrhotic patients while the HO-1
activity and plasma level of CO were related with the severity of PH [20]. Arterial blood gas
analysis showed an increase of COHb in bile-duct-ligated rats which could be reversed by
ZnPP [23]. HO-1 could promote expression of VEGF and thereafter lead to formation of col‐
lateral vessels and higher splanchnic circulation [24].
2.3. Endothelin
Endothelin-1 (ET-1) is the most powerful vasoconstrictor in ETs family [25], which is pri‐
marily synthesized and acts in liver mainly in a paracrine fashion via ET A receptor causing
vessel constriction [26]. In liver cirrhotic rats induced by carbon tetrachloride, both plasma
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ET-1 level and PVP elevated dramatically while the mean hepatic tissue portal inflow re‐
duced. And, perfusion with an antagonist of ET A receptor led to a reduction of plasma ET-1
level and PVP but did not improve the hepatic infusion suggesting that ET-1 was involved
in development of PH [26]. It is consistent with a previous study which had demonstrated
that liver blood inflow fluctuated in ET A and B receptors antagonist infusion groups and
control group [27]. ET A and B receptors play different roles in CCl4-induced portal hyper‐
tensive rats. Antagonism of ET A or B receptor led to a reduced or increased of PVP and
sinusoidal area in the cirrhotic rats respectively [28]. However, activation of ET B receptor
leads to production of other vasoactive molecules, e.g. TXA2 [29]. Besides, antagonism of ET
A receptor alone cannot improve splanchnic circulation indicating ET B receptor plays a role
on regulation in PH [30].
2.4. RAAS
It is well established that renin -angiotensin II (Ang II) -aldosterone -system (RAAS) plays
an important role on body circulation. Ang II promotes proliferation and contraction of HSC
and formation of collagen, leading to liver fibrosis [31]. In hepatorenal syndrome, a severe
complication of cirrhotic portal hypertension with hyperdynamic circulation, systemic re‐
sistance, circulatory renin activity and plasma aldosterone were significantly increased [32].
Besides, angiotensin converting enzyme (ACE) and Ang II elevated in liver cirrhosis [33, 34].
Role of RAAS on portal pressure provides a new therapeutic alternative [35]. Animal model
studies and clinical trials have shown that blockade of Ang II type 1 receptor (AT1R) signifi‐
cantly reduced portal perfusion pressure and HVPG [36-39]. ACE inhibitor also effects to re‐
duce portal pressure in cirrhotic patients [40]. Inhibition of RAAS by losartan could also
lead to a reduction of eNOS and ROS level in BDL rats [41].
2.5. Catecholamines
Catecholamines (CA) cause general physiological changes including increases in heart rate,
blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous sys‐
tem. In BDL cirrhotic rats, noradrenaline correlated with perfusion pressure dose-depend‐
ently, and this constrictive effect might be normalized by phentolamine but not propranolol,
indicating that noradrenaline influences PVP through α-receptor on portal-systemic collater‐
als [42]. In short-term PH induced by partial portal vein ligation (PVL), antagonism of phen‐
tolamine on α-receptor was reduced; meanwhile, release of noradrenaline was down-
regulated as NO up-regulated, indicating a potential role of CA, together with NO, on
hyperhemodynamics and increased PVI [43]. Besides, expressions of tyrosine hydroxylase
and dopamine β-hydroxylase were down-regulated in superior mesenteric artery revealing
genetic regulation of adrenergic neurotransmitter system participating in the splanchnic
vasodilation in PH [44]. Nevertheless, protein level of α-receptor was higher in cirrhotic liv‐
ers than in normal livers; activation of these α-receptors located on HSC induced calcium
spikes and HSC constriction through MAPK, NK-κB and AP-1 pathways, resulting in in‐
creased intrahepatic resistance [45]. When response to β-blockers was defined as a reduction
＞ 10% in HVPG from baseline, the proportion of non-responsers decreased, the rate of first-
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bleeding among them increased and the diagnostic acuracy improved significantly contrast‐
ing with a 20% cut-off value.[46] Also, acute responsers to β-blockers have a better long-
term outcome.[47]
2.6. Cannabinoid
Correlation between Cannabinoid and portal hypertension was paid attention in the last
decades. Administration of anandamide, an endogenous cannabinoid, resulted in a drop of
systemic circulation, mainly mean arterial pressure, although venous pressure changes veri‐
fied, because of its effect on heart rate. Contrastingly, PVI and PVP increased in a dose-de‐
pendent fashion [48]. Treatment with antagonist of cannabinoid CB1 receptor in rats might
lead to an elevation of blood pressure and a reduction of PVI and PVP, indicating cannabi‐
noid is responsible for the dilation of systemic circulation [49]. It is in agreement with hu‐
man. In cirrhotic patients, plasma level of cannabinoid was increased regardless of well-
compensated or not [50]. But things are different in liver. Expression of CB1 receptor was
dramatically down-regulated in both wild-type and eNOS knock-out group mice [9]. How‐
ever, more researches are needed.
2.7. Cyclooxygenase, prostanoids and TXA2
Activation of COX-2/prostanoid pathway promotes production of TXA2 and PGE2 [51]. In
BDL rats,  TXB2,  a stable metabolic of TXA2  in isolated liver perfusate and PVP were in‐
creased in a  time-dependent manner.  Both inhibition of  Kuffer  cells  and COX attenuate
these  changes.  Further  results  indicated  that  COX-2  interact  with  Kuffer  cells-derived
TXA2 was involved and its expression increased significantly [52]. Another group report‐
ed  that  COX-1  and  PGI2  were  responsible  for  decreased  splanchnic  resistance  and  in‐
creased PVI [53, 54].  However, elevated PVP of intrahepatic or pre-hepatic hypertension
rats might be reduced by short-  or long-term administration of COX inhibitor [18].  It  is
consistent  with  Graupera  M et.  al.  [55].  In  BDL portal  hypertensive  rats,  elevated  ET-1
interacted with Kuffer cells, increasing the responsiveness of p38MAPK through ET B re‐
ceptor,  activating cPLA2  and promoting production of TXA2,  contributing to progression
of portal hypertension [29].
2.8. Reactive oxygen species
Reactive oxygen species  (ROS) is  involved in many pathologic  processes.  In the case of
PH, ROS level increases when circulatory NO decreases [56]. Administration of tempol, a
type  of  superoxide  dismutase,  normalizes  these  changes  with  statistical  significance  in
endothelial  cells  and  cirrhotic  liver,  reduces  intrahepatic  vessel  resistance  and  conse‐
quently  increases  PVI  [57].  ROS also  takes  part  in  oxidative  stress  [58],  lipid  peroxida‐
tion,  apoptosis  and  dysfunction  of  endothelial  cells  [41].  Reportedly,  carvedilol,  a  β-
blocker might ameliorate oxidative stress as well as inflammation and fibrosis in a CCl4-
induced liver damage model, by reducing depletion of antioxidant enzyme, formation of
collagen,  and activation  of  NF-κB pathway,  indicating  a  relationship  between ROS and
liver damage and fibrosis [59].
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3. Cytokines and liver fibrosis
Cytokine is a group of soluble protein or polypeptide, regulating immunologic response
and hematopoiesis, participating inflammatory damage and repair. It consists of interleu‐
kins  (IL),  interferons  (IFN),  tumor  necrosis  factors  (TNF),  colony  stimulating  factors
(CSF), chemokines, and growth factors. It has been reported that serum levels IL-6, TNF-
α [60,  61],  and IL-1β [62]  were elevated in hepatoportal  sclerosis,  and plasma IL-6 level
was correlated with the deterioration of liver function [63]. Although IL-6 was increased,
expression  of  IL-6  receptor  in  cirrhotic  liver  was  decreased,  leading  to  a  reduction  of
hepatocyte  response  to  IL-6,  accompanied  by  an  increase  of  gp130,  indicating  gp130
might be the potential negative regulator of liver IL-6 signal pathway [64]. In chronic pa‐
tients  with  hepatitis  C  and/or  schistosomal,  plasma IL-4  level,  as  well  as  ROS,  was  in‐
creased and correlated with portal  vein diameter,  suggesting IL-4 might plays a role on
PVI [65].  A clinical trial has shown that administration of probiotic led to a trend to re‐
duction of  plasma endotoxin,  a mild but significant increase of  TNF-α and a significant
reduction  of  aldosterone  [66].  Besides,  increased  PVP  induced  a  up-regulation  of  α-
smooth muscle actin and collagen ฀ and ethanol exposure enhanced expression of TGF-β
and production of  extracellular  matrix  via  ERK1/2-JNK and p38MAPK pathway respec‐
tively,  leading  to  fibrosis  of  liver  [67].  Reportedly,  IL-18  gene  knock-out  mice  fed  with
methionine-choline-deficient  diet  (MCDD)  showed significant  exacerbated  inflammation,
revealing IL-18 was a negative regulator of non-alcoholic fatty liver disease and non-alco‐
holic steatohepatitis. Tnf mRNA, but not il-6 or il-1b levelm was higher in db/db (Asc-/-)
group than db/db (wt) group, indicating TNF-α expression drove the progression of non-
alcoholic  steatohepatitis  [68].  In  another  type  of  liver  cirrhosis  caused by  chronic  infec‐
tion  of  schistosomiasis,  inflammation  and  following  tissue  repair  led  to  obstruction  of
intrahepatic  vessels  and  increased  intrahepatic  resistance.  These  defenses  in  liver  was
mediated by IL-10.  But  surprisingly,  blockade of  IL-10R resulted in  an elevation of  PH
and a reduction of parasitic antigen specific B cells, but worsened pulmonary accumula‐
tion of  eggs without an increase of  PVP [69].  Co-infection of  bacteria  led to production
of  IL-17  [70].  Consistently,  knock-out  of  IL-10,  IL-12p40,  and IL-13Rα2 contributed to  a
progressive and lethal liver fibrosis, showing the anti-fibrosis effects of these Th2-derived
interleukins in schistosomiasis mansoni treated mice [71].  As demonstrated by Pinter M
et. Al. [72], responders to sorafenib showed a decreased HVPG and VEGF, PDGF, PIGF,
RhoA kinase,  and TNF-α expression,  revealed a  potential  effect  of  these  growth factors
and TNF-α on  HVPG.  And level  of  soluble  TNF-α receptor  in  portal  vein  and hepatic
vein was correlated with model for end-stage liver disease score, in accordance with pre‐
vious studies [73]. However, intrahepatic TNF-α, IL-1β, IL-4, and IL-10 were down-regu‐
lated  while  splanchnic  levels  were  increased  [74].  It  is  shown  that  IFN  is  involved  in
progression of hypertension, especially in viral infection- associated hepatitis [60, 75, 76].
Nowadays, IFN is usually used as antiviral treatment. Combination of 5-fluorouracil and
IFN  might  reduce  the  portal  hypertension  related  events  [77].  Also,  combination  with
IFN enhanced the viral clearance effect of ribavirin [78]. But IFN alone therapy only led
to a temporary reduction of viral DNA load [79]. As documented, TGF-β promotes liver
Vasoactive Substances and Inflammatory Factors in Progression of Liver Cirrhosis with Portal Hypertension
http://dx.doi.org/10.5772/52663
535
fibrosis  in  rats  with  biliary  cirrhosis,  cooperates  with  IFN-γ,  IL-4,  and  TNF-α,  etc  [80].
More studies are needed to illustrate the detail effects of cytokines network on portal hy‐
pertension and liver fibrosis.
4. Molecules in further physiopathological progression
4.1. Splenomegaly and hypersplenism
Volume of spleen or splenomegaly in cirrhotic hypertension patients is primarily attribut‐
ed  to  increased  splanchnic  circulation  and  congestion,  in  which  vasoactive  substances
play  important  roles.  And  the  main  pathologic  changes  are  lower  counts  of  red  blood
cells,  white  blood  cells,  and  platelets.  Compared  to  normal  spleen,  lymphocytes  in  PH
spleen were relatively reduced with a similar distribution;  but total  number of  lympho‐
cytes was increased due to the increase of spleen weight,  with an elevated proliferation
[81, 82].  MicroRNAome analysis showed that microRNA, expecially miR-615-3p was up-
regulated in PH spleen significantly [83, 84]. It targeted on ligand-dependent nuclear re‐
ceptor  corepressor  (LCoR),  promoted  the  phagocytic  capacity  of  macrophages  through
PPARγ pathway [84].  On the other hand, phagocytic capacity of macrophages might be
inhibit  by  Phosphatidylinositol  3-kinase  regulatory  subunit  1  (PI3KR1)  knock-down,  ac‐
companied by down-regulation of  IL-1β and TNF-α [85].  Similarly,  expressions of  IL-1β
and NALP3, a potential NF-κB activator participating in inflammation and immunologic
response  were  up-regulated  significantly  in  CCl4-induced  cirrhotic  PH group compared
to  control  group,  together  with  typical  splenomegaly  histopathological  changes  [86].  In
cirrhotic spleen, different from extrahepatic portal vein obstruction, thromopoietin (TPO)
was reduced and this  reduction is  positively  correlated with exacerbation of  liver  func‐
tion, leading to a decrease of platelet counts [87].
4.2. Esophageal varices
Cirrhotic hypertension is characterized by hyperdynamic circulation and increased intrahe‐
patic resistance as discussed before in this review. Splanchnic vasodilation results in increas‐
ing in HVPG. When HVPG is higher than 12 mmHg, risk of esophageal varices dramatically
increased [88, 89]. Generally speaking, esophageal varices, as well as development of other
collateral vessels, occur after HVPG and is followed by variceal bleeding [90]. Angiogenesis
is associated with esophageal varices and portal hypertension, and expressions of VEGF are
up-regulated, alone or together with TNF-α or PEGF[91-93]. Inhibition of VEGF/VEGF re‐
ceptor pathway led to a decrease in hyperdynamic splanchnic circulation and collateral ves‐
sels [94]. Besides, metabolic disturbances occurred in cirrhotic PH lead to an elevation of
glucagon [95]. The ratio of glycated albumin (GA) to glycated hemoglobin (HbA1c) was as‐
sociated positively with the progression of liver cirrhosis, and patients with elevated GA/
HbA1c ratio have severer esophageal variceal and higher risk of bleeding in HCV-related
cirrhotic patients. This parameter might become a potential biomarker to predict the prog‐
nosis of these patients [96].
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4.3. Ascites
Portal hypertension in cirrhotic liver diseases is a main cause of ascites. As discussed before,
vasoactive substances lead to an elevation of intrahepatic vessels resistance and a relative de‐
crease of blood back-flow to liver. Besides, mechanisms below are involved: 1) hyperdynamic
circulation. Hyperdynamic circulation is associated with disturbance of vasoactive substances.
It is characterized by increased cardiac index and plasma volume and decreased systemic and
splanchnic resistance [90]. 2) hypoalbuminemia following damage of liver function. One of the
hyperalbuminemia occurred in cirrhotic PH is dysfunction of hepatocytes. In is shown that hy‐
pertension is a negative regulator to the number and structure of hepatocytes [97]. Poor blood
supply induced by liver fibrosis and disturbance of hemodynamics results in intrahepatic hy‐
poxia and damage of hepatocytes. Besides, primary liver diseases also cause inflammation and
damage in liver. 3) renal function changes. This part will be discussed below.
4.4. Hepatorenal syndrome
It is well established that main cause of hepatorenal syndrome (HRS) is constriction of vessels in
kidney induced by reduction of effective circulating blood volume (ECBV). As discussed previ‐
ously, ECBV is reduced by systemic and splanchnic vasodilation induced by changes of NO, ET,
PGs and TXA2. Besides, some localized physiopathologic should be paid attention on. Expres‐
sion of HO-1 in kidney was significantly reduced in BDL-induced cirrhotic rats [98]. Cyctatin C
was increased in decompensated liver cirrhosis and HRS, thus it could be used as a predictor of
HRS [99, 100]. Additionally, plasma level of ADAMTS13 was decreased and supplemental ther‐
apy might improve prognosis of patients with severe liver cirrhosis and HRS [101, 102].
4.5. Hepatic encephalopathy
Hepatic encephalopathy (HE) in portal hypertension is defined as C type HE. In PVL-in‐
duced PH rats, chemokine changes in splanchnic system, liver, and central nervous system
(CNS) are different [103]. As reported, in CNS, CX3CL1/CX3CR1 and SDF1-α/CXCR4 were
increased. The former one promotes inflammation in CNS while the latter one modulates
neuron activity through inhibitory neurotransmitters, e.g. gamma-amino butyric acid (GA‐
BA) [104]. ROS also participates in pre-hepatic portal hypertension [105, 106]. GABA level is
also negatively regulated by dehydroepiandrosterone sulfate (DHEAS), which reduced in
cirrhotic HE [107]. Besides, IL-6 has synergistic effect with ammonia in cirrotic HE patients
[108]. Ammonia impairs brain eNOS activity, leading to significant abnormality of NO regu‐
lation and disturbance of blood supply [109]. Due to liver dysfunction in HE patients, ele‐
vated plasma manganese also indicates a bad prognosis [110].
5. Conclusion
Portal hypertension concerns a great number of molecules and complicated physiopatholog‐
ic mechanisms. It can be classified into pre-, intra-, and post-hepatic PH according to the pri‐
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mary disease, with similar but not same involvement of molecules and mechanisms.
However, we can still conclude that: 1) vasoactive substances play an important in systemic,
splanchnic, hepatic, and even neurologic circulations which are closely related to blood sup‐
ply, affecting the development, progression, and outcome of PH; 2) imbalance of pro-/anti-
inflammatory cytokines lead to a systemic and/or localized regulation of signal pathways
and modulate gene expression and silencing, cell proliferation and apoptosis, tissue damage
and repair, and eventually life and death; 3) accumulating research advancements provide
us new targets for treatment of PH, but it has a long way to go from bench to bedside.
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